A Phase 2 interventional study of Pamiparib and Placebo in Advanced or Inoperable Gastric Cancer, sponsored by BeiGene. Completed at 65 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,186 studies in Stomach Neoplasms with a site in China — 482 open to participants now, 559 under way, 50 of them phase 3. Stomach Neoplasms · China.
Among the 1,186 studies in Stomach Neoplasms with a site in China, this one is the 330th largest by enrollment of the 883 interventional ones that give a count, is one of 58 that started in 2018, is one of 323 in phase 2, and was the 311th registered.
3,406 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →482 of the 1,186 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:
Hua Huang, MD, PhD · Sites in China
Ages 18–70
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Healthy volunteers
Akeso · Sites in China, United States, Germany and 1 more country
Ages 18+
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Jie Yuan,MD · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,186 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 167 · Phase 2 421 · Phase 3 146 · Phase 4 25
First in 1997; this study’s year is marked. 58 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 66 across 2,505 interventional studies indexed under Stomach Neoplasms.
Median enrollment 87 across the 883 interventional studies, 300 across the 303 observational. Of the 270 that completed or were terminated, 28 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
210 of 1,186 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 6 studies filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
122 of the studies in Stomach Neoplasms with a site in China that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06221748Phase 3RemeGen Co., Ltd.DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | 2026-12 |
| NCT05918094Phase 3Sun Yat-sen UniversityComparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma | 2026-12 |
| NCT06939439Phase 3The First Affiliated Hospital with Nanjing Medical UniversityUsing ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer | 2026-12-31 |
| NCT06177041Phase 3FutureGen Biopharmaceutical (Beijing) Co., LtdM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. | 2027-01-11 |
| NCT06532006Phase 3Shanghai Henlius BiotechA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | 2027-06-01 |
Add all 122 to your calendar (.ics) → With an account.
Among the 1,186 studies in Stomach Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants received BGB-290; in Arm B participants received placebo. The purpose of this study is to show that BGB-290 (pamiparib) (versus placebo) will improve progression-free survival (PFS) in participants with advanced or inoperable gastric cancer.
This is a double-blind, placebo controlled, randomized multicenter global phase 2 study comparing the efficacy and safety of single agent poly (ADP-ribose) polymerase (PARP) inhibitor BGB-290 to placebo as maintenance therapy in participants with advanced gastric cancer who have responded to first line platinum based chemotherapy. Participants are randomized 1:1 to BGB-290 (Arm A) or placebo (Arm B). Randomization will be stratified by geography, biomarker status, and ECOG performance status.
Participants will undergo tumor assessments at screening and then every 8 weeks, or as clinically indicated. Administration of BGB-290 or placebo will continue until disease progression, unacceptable toxicity, death, or another discontinuation criterion is met.
After end of treatment, long-term follow-up assessments include tumor imaging every 8 weeks for those participants without disease progression, survival status, and new anticancer therapy.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received pamiparib orally.
Drug: Pamiparib
Participants received placebo orally.
Drug: Placebo
60 mg orally twice daily
Also known as: BGB-290
60 mg orally twice daily
Progression Free Survival (PFS) by Investigator Assessment
PFS is defined as the time from randomization to progressive disease (PD) per Response Evaluation Criteria in Solid Tumors ( RECIST) Version 1.1 by investigator assessment or death due to any cause, whichever occurs first.
Time frame: Approximately 23 months
Overall Survival (OS)
OS is defined as the time from randomization to death due to any cause.
Time frame: Approximately 23 months
Time To Second Subsequent Treatment (TSST)
TSST is defined as the time from randomization until the second subsequent anticancer therapy or death after next-line therapy
Time frame: Approximately 23 months
Objective Response Rate (ORR)
ORR is defined as the percentage of participants with a best overall response of Complete Response or Partial Response per RECIST Version 1.1 by investigator assessment
Time frame: Approximately 23 months
Duration of Response (DOR)
DOR is defined as the time from the first documented confirmed response of Complete Response or Partial Response to progressive disease (PD) per RECIST Version 1.1 by investigator assessment or death due to any cause, whichever occurs first
Time frame: Approximately 23 months
Time To Response
Time to response is defined as the time from randomization to the first documented response of Complete Response or Partial Response per RECIST Version 1.1 by investigator assessment
Time frame: Approximately 23 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From start of study treatment until 30 days after the last study drug intake or initiation of new anticancer therapy, whichever occurs first (up to approximately 4 years and 5.5 months)
Participants were enrolled in multiple study centers in Asia, Australia, Europe, and North America.
| Milestone | Pamiparib | Placebo |
|---|---|---|
| Started | 71 | 65 |
| Completed | 0 | 0 |
| Not completed | 71 | 65 |
| Withdrew: Withdrawal by subject | 4 | 4 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Death | 42 | 31 |
| Withdrew: Sponsor's decision | 1 | 0 |
| Withdrew: Investigator's decision | 1 | 2 |
| Withdrew: Disease progression | 1 | 0 |
| Withdrew: Treatment completed | 0 | 1 |
| Withdrew: Sponsor's decision to end study | 21 | 25 |
| Withdrew: Transfer to long term extension study | 1 | 0 |
PFS is defined as the time from randomization to progressive disease (PD) per Response Evaluation Criteria in Solid Tumors ( RECIST) Version 1.1 by investigator assessment or death due to any cause, whichever occurs first.
| Months | Pamiparib | Placebo |
|---|---|---|
| Progression Free Survival (PFS) by Investigator Assessment | 3.7 (1.94 to 5.26) | 2.1 (1.87 to 3.75) |
OS is defined as the time from randomization to death due to any cause.
| Months | Pamiparib | Placebo |
|---|---|---|
| Overall Survival (OS) | 10.2 (8.71 to 16.33) | 12.0 (8.21 to NA) |
TSST is defined as the time from randomization until the second subsequent anticancer therapy or death after next-line therapy
| Months | Pamiparib | Placebo |
|---|---|---|
| Time To Second Subsequent Treatment (TSST) | 9.8 (8.05 to 10.94) | 9.7 (7.49 to 14.00) |
ORR is defined as the percentage of participants with a best overall response of Complete Response or Partial Response per RECIST Version 1.1 by investigator assessment
| Percentage of participants | Pamiparib | Placebo |
|---|---|---|
| Objective Response Rate (ORR) | 7.7 (1.62 to 20.87) | 6.3 (0.77 to 20.81) |
DOR is defined as the time from the first documented confirmed response of Complete Response or Partial Response to progressive disease (PD) per RECIST Version 1.1 by investigator assessment or death due to any cause, whichever occurs first
| Months | Pamiparib | Placebo |
|---|---|---|
| Duration of Response (DOR) | 3.6 (3.48 to NA) | NA (5.55 to NA) |
Time to response is defined as the time from randomization to the first documented response of Complete Response or Partial Response per RECIST Version 1.1 by investigator assessment
| Months | Pamiparib | Placebo |
|---|---|---|
| Time To Response | 3.68 (1.8 to 7.3) | 1.87 (1.87 to 1.9) |
| Number of participants | Pamiparib | Placebo |
|---|---|---|
| Participants With At Least 1 TEAE | 66 | 61 |
| Participants with Serious TEAEs | 17 | 11 |
Collected over From start of study treatment until 30 days after the last study drug intake or initiation of new anticancer therapy, whichever occurs first (up to approximately 4 years and 5.5 months). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pamiparib | 42/71 (59.2%) | 17/71 (23.9%) | 65/71 (91.5%) |
| Placebo | 31/65 (47.7%) | 11/65 (16.9%) | 57/65 (87.7%) |
| Event | Pamiparib | Placebo |
|---|---|---|
| DysphagiaGastrointestinal disorders | 0/71 | 3/65 |
| AnaemiaBlood and lymphatic system disorders | 3/71 | 1/65 |
| Obstruction gastricGastrointestinal disorders | 0/71 | 2/65 |
| VomitingGastrointestinal disorders | 2/71 | 0/65 |
| DeathGeneral disorders | 2/71 | 0/65 |
| PneumoniaInfections and infestations | 2/71 | 1/65 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/71 | 1/65 |
| Malignant dysphagiaGastrointestinal disorders | 0/71 | 1/65 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/71 | 1/65 |
| SepsisInfections and infestations | 0/71 | 1/65 |
| Event | Pamiparib | Placebo |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 25/71 | 10/65 |
| NauseaGastrointestinal disorders | 23/71 | 12/65 |
| Decreased appetiteMetabolism and nutrition disorders | 19/71 | 9/65 |
| VomitingGastrointestinal disorders | 16/71 | 2/65 |
| AstheniaGeneral disorders | 16/71 | 12/65 |
| Abdominal painGastrointestinal disorders | 9/71 | 13/65 |
| DiarrhoeaGastrointestinal disorders | 13/71 | 9/65 |
| Abdominal pain upperGastrointestinal disorders | 12/71 | 7/65 |
| ConstipationGastrointestinal disorders | 9/71 | 9/65 |
| Peripheral sensory neuropathyNervous system disorders | 4/71 | 9/65 |
Intent to Treat (ITT) Analysis Set included all randomized participants who were assigned to a study drug (pamiparib or placebo)
| Age, Continuous(years) | Pamiparib | Placebo | Total |
|---|---|---|---|
| Mean | 62.5 ± 9.82 | 62.1 ± 11.23 | 62.3 ± 10.48 |
| Sex: Female, Male(Participants) | Pamiparib | Placebo | Total |
|---|---|---|---|
| Female | 25 | 20 | 45 |
| Male | 46 | 45 | 91 |
| Ethnicity (NIH/OMB)(Participants) | Pamiparib | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 9 |
| Not Hispanic or Latino | 53 | 50 | 103 |
| Unknown or Not Reported | 14 | 10 | 24 |
| Race/Ethnicity, Customized(Participants) | Pamiparib | Placebo | Total |
|---|---|---|---|
| Asian | 20 | 15 | 35 |
| Black or African America | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| White | 38 | 36 | 74 |
| Other | 1 | 3 | 4 |
| Not Reported/Unknown | 12 | 8 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Jul 2018 to primary completion in Jun 2020, 23 months.
Results were first posted in Sep 2023, 3 years 3 months after primary completion. A results delay was requested in Sep 2021.
Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 23 months is below that.
Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pamiparib